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Abstract: Heat shock proteins (HSPs) are a large family of proteins highly conserved throughout
evolution because of their unique cytoprotective properties. Besides assisting protein refolding and
regulating proteostasis under stressful conditions, HSPs also play an important role in protecting
cells from oxidative stress, inflammation, and apoptosis. Therefore, HSPs are crucial in counteracting
the deleterious effects of hyperglycemia in target organs of diabetes vascular complications. Changes
in HSP expression have been demonstrated in diabetic complications and functionally related to
hyperglycemia-induced cell injury. Moreover, associations between diabetic complications and
altered circulating levels of both HSPs and anti-HSPs have been shown in clinical studies. HSPs thus
represent an exciting therapeutic opportunity and might also be valuable as clinical biomarkers.
However, this field of research is still in its infancy and further studies in both experimental diabetes
and humans are required to gain a full understanding of HSP relevance. In this review, we summarize
current knowledge and discuss future perspective.
Keywords: diabetes; diabetes complications; diabetic retinopathy; diabetic nephropathy; diabetic
retinopathy; diabetic neuropathy; heat shock proteins; Heat shock protein (HSP) 27; HSP47; HSP60;
HSP70; HSP90; biomarkers; albuminuria
1. Introduction
Vascular complications are the major causes of morbidity and mortality in people with diabetes
(DM). Although their underlying mechanisms are not fully understood, advanced glycated end
products (AGEs), oxidative stress, and a low-grade inflammation are believed to play a key role in
mediating hyperglycemia-induced cell dysfunction and damage [1]. There is thus the need to identify
therapies either blocking cascades leading to cell injury or enhancing the effectiveness of endogenous
cytoprotective machineries.
Heat shock proteins (HSPs) are a family of proteins highly conserved throughout evolution
because of their key role in cytoprotection. Both pharmacological and genetic modulation of HSP
expression has been tested in animal models as a strategy to enhance cytoprotection in the context of
DM. Moreover, the discovery that HSPs can be released in the extracellular space has prompted clinical
studies investigating the potential use of both HSPs and anti-HSP antibodies as serum biomarkers of
DM complications.
In this review, we summarize current knowledge of the role of HSP27, HSP47, HSP60, HSP70,
and HSP90 in DM complications and discuss the potential clinical relevance.
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2. Diabetes Micro and Macrovascular Complications
People with DM are two to four times more likely to develop macrovascular diseases, such as
coronary artery disease, stroke, and peripheral vascular disease. Moreover, cardiovascular events are
the predominant cause of death in patients with DM [2].
Microvascular complications, affecting the eye, the kidney, and the nervous system, also have a
significant impact. In the Western World diabetic nephropathy (DN) is a leading cause of end stage
renal disease requiring renal replacement therapy. Additionally, patients with DN have an increased
risk of cardiovascular morbidity and mortality. Hyperglycemia, hypertension, and a low-grade
inflammation are the major determinants of the renal damage, comprising podocyte injury, mesangial
matrix accumulation, tubule-interstitial fibrosis and resulting in albuminuria and progressive renal
function decline [1,3].
Diabetic retinopathy (DR), the major cause of blindness in adults, is characterized by apoptosis
of both pericytes and retinal endothelial cells, leading to disruption of the blood-retinal barrier and
capillary loss. Vascular damage causes retinal ischemia and overexpression of angiogenic factors,
which are responsible for the abnormal retinal neovascularization that characterizes the advanced
proliferative phase of the complication [4].
DM also affects both the central and peripheral nervous system. Distal symmetric polyneuropathy
(DSP), the most prevalent form of diabetic neuropathy, is due to axon degeneration secondary to both
metabolic abnormalities and microvessel injury. DSP affects predominantly sensory neurons and causes
paraesthesia, allodynia, hyperalgesia, and subsequently hypoalgesia [5]. In the central nervous system
(CNS), DM induces a variety of functional alterations resulting in cognitive deficits that are collectively
referred to as diabetic central neuropathy. Structurally, there is neuronal apoptosis and proliferation
of both astrocytes and microglia in several brain areas and particularly in the hippocampus that is
important in both learning and memory and highly susceptible to oxidative stress [6].
3. Heat Shock Proteins
Heat shock proteins (HSPs) are ubiquitous proteins classified in various families based on
their molecular weight (HSP100, HSP90, HSP70, HSP60, HSP40, and small HSPs). Recently, a new
classification has been proposed that divide HSPs in the following groups: HSPH (HSP110), HSPC
(HSP90), HSPA (HSP70), DNAJ (HSP40), HSPB (small HSP) and the chaperonin families HSPD/E
(HSP60/HSP10) and TRiC (also known as chaperonin-containing TCP-1 or CCT) [7] (Table 1).
Table 1. HSP Proteins Subfamilies—Classifications.
HSP Names Old Names
HSPB
HSPB1 HSP27; CMT2F; HMN2B; HSP28; HSP25; HS.76067; DKFZp586P1322
HSPB2 HSP27; MKBP; Hs.78846; LOH11CR1K; MGC133245
HSPD1 HSP60; GroEL
HSPA
HSPA1A HSP70-1; HSP72; HSPA1
HSPA1B HSP70-2
HSPA2 Heat-shock 70kD protein-2
HSPA5 BIP; GRP78; MIF2
HSPA8 HSC70; HSC71; HSP71; HSP73
HSPA9 GRP75; HSPA9B; MOT; MOT2; PBP74; mot-2
HSPC
HSPC1 HSP90AA1; HSPN; LAP2; HSP86; HSPC1; HSPCA; HSP89; HSP90;HSP90A; HSP90N; HSPCAL1; HSPCAL4; FLJ31884
HSPC2 HSP90AA2; HSPCA; HSPCAL3; HSP90
HSPC3 HSP90AB1; HSPC2; HSPCB; D6S182; HSP90B; FLJ26984; HSP90
HSPC4 HSP90B1; ECGP; GP96; TRA1; GRP94; endoplasmin
HSPC5 TRAP1; HSP75; HSP90L
Int. J. Mol. Sci. 2017, 18, 2709 3 of 26
HSPs comprise both constitutively expressed and inducible forms. Induction of HSPs occurs in
response to stressors, such as thermal and osmotic stress, heavy metals, hypoxia, ischemia, and it is
orchestrated by the transcription factor heat shock factor 1 (HSF1), which is the master regulator of the
“stress response” [8].
As molecular chaperones, HSPs regulate the biosynthesis, folding/unfolding, transport, and
assembly of cellular proteins and some HSPs also favour activation of associated proteins. Following
cellular stress, induced HSPs facilitate refolding, prevent aggregation of misfolded proteins, and assist
in the proteasomal degradation of irreversibly damaged proteins. Furthermore, HSPs inhibit
apoptosis, protect against both oxidative stress and inflammation, and increase resistance to subsequent
stresses (tolerance).
Although HSPs are predominantly intracellular cytoprotective machineries, they can also be
exposed on the plasma membrane and released in the extracellular space, resulting in detectable
levels of HSPs in the bloodstream. As HSPs do not possess signal sequences, they are not exported
through the classical endoplasmic reticulum (ER)-Golgi complex secretory pathway and alternative
mechanisms, including release within exosomes, are involved [9]. Extracellular HSPs have been
implicated in cell-cell communication and both immune and inflammatory processes.
3.1. Heat Shock Protein 47—SerpinH1
Heat shock protein 47 (HSP47), a glycoprotein localized in the ER, is a collagen-specific chaperone.
In particular, HSP47 inhibits collagen aggregation by binding to pro-collagen in the ER and facilitate
triple helix formation. Gene ablation studies confirmed that HSP47 is essential for collagen maturation
as HSP47-deficient cells contained misfolded pro-collagen aggregates in the ER that were then degraded
by autophagy [10].
In the context of DM, most of the research has focused on the role of HSP47 in DN as excessive
accumulation of extracellular matrix components, including collagen, is both a characteristic feature
of DN and a key determinant of renal function loss. There is evidence of HSP47 overexpression in
both human and experimental DN. A study performed on renal tissue from patients with DN has
shown that overexpression of type III collagen in the interstitial space and of type IV collagen in
the sclerotic glomeruli co-localized with an enhanced HSP47 expression by renal resident cells [11].
Similarly, in advanced experimental DN, expression of HSP47 was increased in mesangial cells, stressed
podocytes, and tubular epithelial cells in parallel with increased both type III and type IV collagen
deposition, glomerulosclerosis, and tubulointerstitial fibrosis [12]. Furthermore, HSP47 was induced
during epithelial-mesenchymal transition, a key event underlying the development of renal fibrosis in
chronic kidney diseases, including DN [13].
Formation of AGEs has been implicated in DM-induced HSP47 overexpression. In experimental
diabetes, OPB-9195, an inhibitor of AGE formation, prevented not only transforming growth factor
(TGF)-β1 and collagen expression, but also HSP47 induction [14]. Also, exposure of mesangial
cells to AGEs induced HSP47 expression in a TGF-β1-dependent manner [14]. Although the
intracellular signalling pathway whereby TGF-β1 induces HSP47 remains to be fully elucidated,
in vitro experiments on proximal tubular cells suggest that activation of the signalling molecules
extracellular signal-regulated kinase 1/2 (ERK1/2) and Jun kinase (JNK) is involved [15]. Moreover, in
non-renal cells TGF-β1 can also enhance HSP47 expression by inhibiting microRNA-29b [16].
Inhibition of HSP47 has been proposed as a strategy for the management of fibrotic disorders and
studies in a variety of murine models of fibrosis confirmed that knocking-down HSP47 decreased the
accumulation of collagen and prevented fibrosis, as recently reviewed [17]. Although there are no data
on HSP47 blockade/ablation in DN, studies performed in experimental both glomerulonephritis and
tubulo-interstitial fibrosis have provided a proof of concept that HSP47 suppression can ameliorate
renal fibrosis [18–20]. However, autophagy is impaired in DN and HSP47 deletion caused accumulation
of pro-collagen aggregates leading to apoptosis in cells with altered autophagy [21]; therefore,
the potential benefit of HSP47 blockade in DN must be confirmed. Of interest, a recent screening of
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compounds that inhibit the interaction between HSP47 and collagen has identified AK778 and its
cleavage product Col003 as molecules that can inhibit collagen secretion [22] and these compounds
might be exploited in the future for pharmacological intervention.
There are limited data on the potential role of HSP47 in other chronic complications of DM.
However, collagen production is important in the healing process and HSP47 expression in wounds was
reduced in both human and experimental diabetes [23,24], suggesting that insufficient HSP47 induction
may interfere with wound healing in the context of DM. This implies that potential intervention
strategies reducing HSP47 expression to protect the kidney may have the disadvantage to delay wound
repair (Figure 1).
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Figure 1. Role of HSP47 in Diabetic Complications. T e collagen-specific ch peron HSP47 is
overexpressed (up arrow) in experimental diabetic nephropathy and downregulated (down arrow) in
diabetic wounds. This is paralleled by consensual changes in collagen expression and may be relevant
in renal fibrosis and wound healing. TGF-β1: transforming growth factor-β1; ?: unproven hypothesis.
In summary, HSP47, which is impor nt in collagen maturation, is upregulated in DN and
downregulated in diabetic wounds with parallel changes in collagen levels. However, evidence of a
beneficial effect of therapeutic strategies targeting HSP47 in these conditions is lacking.
3.2. Heat Shock Protein 27—HSPB1
HSPB1 (also known as HSP27 in both humans and rats and HSP25 in mice) belongs to the family
of the small HSPs. Besides having a molecular chaperon function, HSPB1 stabilises the cytoskeleton
through its actin-capping activity, prevents apoptosis, nd reduces oxidative tress by i creasing both
glutathione levels and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) activity. HSPB1 forms
high molecular weight multimers and undergoes multiple phosphorylations predominantly through a
p38 mitogen-activated protein kinase (p38MAPK)/MAPK-activated protein 2 (MK2) pathway. In vitro,
phosphorylation leads to disaggregation of HSPB1 multimers, possibly affecting HSPB1 both cellular
localization and function. Moreover, phosphorylation favours actin polymerization by inhibiting
HSPB1 actin-capping activity [25]. Finally, HSPB1 can also be released into the extracellular space
through both lysoendosomal and exosomal pathways [26].
3.2.1. Diabetic Nephropathy
Podocytes are important constituent of the glomerular filtration barrier and the slit diaphragm,
a junction connecting the foot processes of neighbouring podocytes, is the major restriction site to
glomerular protein filtration. DM alters podocyte both function and structure and this eventually
leads to podocyte foot processes effacement, apoptosis, and proteinuria [1]. Given the important role
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of HSPB1 in both inhibiting apoptosis and controlling cytoskeleton dynamics, HSPB1 is expected to
be relevant in podocyte pathophysiology. Consistent with this notion, HSPB1 is highly expressed
by podocytes in the normal kidney [27]. Moreover, in experimental DM there was an increased
glomerular expression of either total or phosphorylated HSPB1 [27–30], particularly in podocytes,
and a transition from large to small HSPB1 oligomers in isolated diabetic glomeruli [31]. Moreover,
exposure of cultured podocytes to high glucose, angiotensin II, and mechanical stretch to mimic
glomerular hypertension enhanced HSPB1 either expression [28] or phosphorylation [27] and silencing
of HSPB1 exacerbated high-glucose-induced podocyte apoptosis [28].
Likely, HSPB1 phosphorylation/induction is a cytoprotective mechanism aimed to limit
both oxidative stress and apoptosis. However, HSPB1 phosphorylation causes actin uncapping
and may reduce the stability of the podocyte cytoskeleton that is crucial in podocyte function.
In keeping with this hypothesis an increase in both total and phosphorylated HSPB1 was reported
in puromycin-induced nephrotic syndrome [32]. Deletion of MK2, which phosphorylates HSPB1,
was not beneficial in an animal model of streptozotocin (STZ)-induced diabetes, failing to show a
functional relevance of the p38/MK2/HSPB1 pathway in DN [29]. However, HSPB1 phosphorylation
was not entirely abrogated in these mice because other kinases can phosphorylate HSPB1 beside MK2;
therefore, strategies that completely block phosphorylation are required to clarify the potential role of
HSPB1 in the pathogenesis of the diabetic proteinuria.
There are no data on circulating levels of HSPB1 in DN except for a small study that reported a
rise in plasma HSPB1 levels in patients with type 2 DM (DM2) and DN compared with DM2 subjects
without any chronic complications [33].
3.2.2. Diabetic Retinopathy
Both expression profiling and next generation sequencing analyses of the retina from STZ-induced
diabetic mice showed that HSPB1 is overexpressed in early as well as advanced DR [34–36].
This is considered a compensatory response to counteract DM-induced both oxidative stress and
apoptosis [37]. Although data on the expression of HSPB1 protein are more conflicting with some
studies reporting enhanced [38,39] and others reduced [40,41] HSPB1 expression, the phosphorylated
form of HSPB1 was increased in the diabetic retina and inhibition of HSPB1 phosphorylation using a
p38 inhibitor ameliorated the retinal vascular injury in vivo [38]. DM also affects the neural components
of the retina and induces apoptosis of retinal ganglion cells (RGC) that are of critical importance to the
visual system. HSPB1 is not constitutively expressed by RGC, but can be induced by stresses [42] and
we found that in RGC from diabetic mice there was an overexpression of both HSPB1 and markers of
oxidative stress and apoptosis [39].
Recently, HSPB1 has also been implicated in the neovascularization of the retina. This is based
predominantly on in vitro studies on endothelial cells, highlighting a complex interaction between
HSPB1 and vascular endothelial growth factor (VEGF), the major inducer of retinal neovascularization
in DR. VEGF promoted HSPB1 phosphorylation via a stress-activated protein kinase 2 (SAPK-2)/p38
pathway, thus favouring both cytoskeleton reorganization and endothelial cell migration, possibly
supporting angiogenic sprouting [43]. Moreover, HSPB1 phosphorylation reduced the release of
HSPB1 in the extracellular space, where extracellular HSPB1 (eHSPB1) binds to and blocks VEGF [44],
but also enhanced intracellular VEGF expression by engaging the Toll-Like Receptor 3 (TLR3) on
endothelial cells [45]. Although the relevance of these findings to proliferative DR remains to be
proven, they underscore the importance of both intracellular and extracellular HSPB1 in fine-tuning
VEGF pro-angiogenic activity.
3.2.3. Diabetic Neuropathy
HSPB1 is considered highly relevant in neurons both function and protection. Accordingly, HSPB1
mutations can cause hereditary polyneuropathies [46,47] and induction of HSPB1 is crucial in both
axonal regeneration and neuron survival in experimental models of axon injury [48,49].
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Both atrophic and degenerative changes of dorsal root ganglia (DRG) neurons have been described
in animal models of DM, though DRG neurons are relatively preserved compared to those in animal
models of axotomy. Data on HSPB1 expression in DRG neurons are conflicting. A study did not
find any change, while HSPB1 was the only marker of plasticity/stress to exhibit enhanced gene
expression in another report [50,51]. However, there is evidence of a beneficial effect of HSPB1
in DSP as HSPB1 overexpression in neurons of diabetic mice conferred protection against a range
of neuropathic abnormalities, including loss of footpad thermal sensation, mechanical allodynia,
loss of epidermal innervation, reduced sensory conduction velocity [52]. In DM, changes of HSPB1
expression have also been shown in the CNS. Indeed, HSPB1 was overexpressed in the hippocampus
of STZ-induced diabetic mice, predominantly in CA1 neurons and activated glial cells, and this was
paralleled by astrogliosis and overexpression of oxidative stress markers [53].
Circulating levels of HSPB1 have also been proposed as a biomarker of DSP. In the large cohort
of patients with type 1 DM (DM1) of the EURODIAB PCS study, we found that higher circulating
HSPB1 levels conferred a twofold increased risk of DSP, independently of known risk factors and
confounders [54]. Although the mechanism of the rise of serum HSPB1 levels in patients with DSP is
unclear, this finding is of relevance as the lack of circulating markers for DSP represents an important
limit of clinical research in the field. This association appears specific of DSP in DM1, as no association
was found with autonomic neuropathy [55] and even an inverse association reported in DM2 [56].
However, prospective studies exploring the potential relevance of HSPB1 as a positive predictor of
DSP have not yet been performed.
3.2.4. Diabetic Macrovascular Diseases
HSPB1 is considered of relevance in vascular homeostasis because of its anti-apoptotic and
chaperon properties. Moreover, HSPB1 also controls the actin cytoskeleton, suggesting a potential
involvement in vascular remodelling. In human atherosclerotic plaques, there is a reduction in
both total and phosphorylated HSPB1 expression [57–60]. HSPB1 downregulation is even greater
in complicated lesions, raising the possibility that HSPB1 deficiency plays a role in atherosclerosis
progression. In keeping with this, in high fat diet-fed (HFD)-ApoE−/− mice, HSPB1 overexpression
ameliorated the phenotype of atherosclerotic plaques, reducing lesion area, cholesterol content,
apoptosis, and macrophage accrual, while increasing intimal both vascular smooth muscle cells
(VSMC) and collagen content [61]. Although there are no available data in diabetic animals, inhibition
of HSPB1 phosphorylation enhanced apoptosis in endothelial cells exposed to high glucose [62].
Moreover, a reduction in GAPDH activity is considered a converging point of multiple deleterious
pathways activated by hyperglycemia and a key step in the pathogenesis of DM complications [63];
therefore, the ability of HSPB1 to activate GAPDH may be particularly advantageous in DM.
HSPB1 is also released in the extracellular space and recent studies suggest that eHSPB1 plays an
important role in atherosclerosis. HSPB1 secretion was drastically reduced in atherosclerotic lesions
and almost abolished in complicated plaques [58]. Extracellular HSPB1 appears to diminish the lipid
engulfment of monocyte/macrophages by both reducing the uptake of atherogenic lipoproteins and
enhancing cholesterol efflux. Indeed, eHSPB1 was shown to block and downregulate the macrophage
scavenger receptor A [64,65]. Moreover, binding of eHSPB1 to the macrophage TLR4 induced
the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB)-mediated release of the
granulocyte-macrophage colony-stimulating factor (GM-CSF), which in turn promoted cholesterol
efflux by enhancing ATP-binding cassette (ABC) transporter activity [66]. Accordingly, in vivo in
ApoE−/− mice, HSPB1 overexpression significantly decreased cholesterol content in the plaque area
via a GM-CSF-dependent mechanism [66]. On the other hand, eHSPB1 may also have deleterious
effects as binding of eHSPB1 to endothelial TLR2-3-4 activates NF-κB [45,67]. Moreover, the release of
phosphorylated HSPB1 from platelets was correlated to accelerated platelet aggregation in patients
with DM2 [68,69].
Int. J. Mol. Sci. 2017, 18, 2709 7 of 26
Clinical studies have explored if changes in circulating HSPB1 occur in a mixed population
of non-diabetic and DM2 patients with CVD. Serum HSPB1 levels were increased in patients with
acute coronary syndrome [60] and ischemic stroke [70], likely because of cell injury. On the contrary,
they were reduced in patients with stable CVD and predicted subsequent major clinical events in
patients with established CAD, but not in a primary prevention cohort [58,71–73]. At variance, we did
not observe any association between HSPB1 and CVD in patients with DM1 [54]. Although the
presence of HSPB1 autoantibodies in the serum may represent a potential confounder by shielding
HSPB1, there was no difference in anti-HSPB1 levels between DM1 patients with and without vascular
complications [74].
In summary, levels of HSPB1/phosphorylated HSPB1 are either unchanged or enhanced in
diabetes microvascular complications. On the contrary, both total and phosphorylated HSPB1 are
downregulated in atherosclerotic plaques and even more in the unstable ones. There is evidence of a
beneficial effect of HSPB1 overexpression in animal models of atherosclerosis and in diabetic animals
with DSP. Circulating levels of HSPB1 have been proposed as a biomarker of DSP (Figure 2).
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Figure 2. HSPB1/HSP27 in Diab tic Complicati ns. HSPB1/HSP27 has anti-apoptotic and
anti-oxidative effects and controls cell migration acting on the actin cytoskeleton. Expression of
total and/or phosphorylated HSPB1/HSP27 (P-HSPB1/HSP27) is altered (up arrow: overexpressed;
down arrow: downregulated) in target orga s of diabetic complications (neurons, kidney, retina, vessel
wall). HSPB1/HSP27 has neuroprotective effects and stabilizes atherosclerotic plaques. The role of
HSPB1/HSP27 in diabetic nephropathy and retinopathy is undetermined; however, HSPB1/HSP27 is
considered cytopr tective, while -HSPB1/HSP27 might have deleterious effects (proteinuria, retinal
neovascularization). ?: unproven hypothesis.
3.3. Heat Shock Protein C—HSP90
The highly conserved HSPC/HSP90 family c mprises 5 members HSPC1/HSP90AA1
(cytosol inducible), HSPC2/HSPAA2 (cytosol inducible), HSPC3/HSPAB1 (cytosol constitutive),
HSPC4/GRP94 (ER), and HSPC5/TRAP1 (mitochondria), but most of the stu ies in DM complications
were performed on the cytos lic members of this family.
The biological activity of HSPC as chaperon depends on its capacity to bind and hydrolyse ATP,
which drives the closed conformation of active HSPC. Besides its chaperon function, HSPC facilitates
the maturation of hundreds of proteins, also named “clients”, that are involved in a variety of cellular
processes, including cell survival, signal transduction, transcriptional regulation, and inflammation.
A large number of co-chaperones, including HSPA/HSP70, interact with HSPC and regulates its
conformational changes during client processing. The transcription factor HSF1 is not only an inducer,
but also a client of HSPC. In fact, the HSPC-HSPA complex binds to HSF1 and keeps it in an inactive
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state. If chaperones are required elsewhere and no longer available for HSF1 inhibition, free HSF1
moves to the nuclei with subsequent increase of heat shock gene transcription. Therefore, HSPC links
the stress status of cells to HSP gene expression [75].
As HSPC can promote cell survival, migration, inflammation, and angiogenesis, it is considered
a very promising target in cancer therapy. This has led to development of specific HSPC inhibitors
and today more than a dozen of HSPC inhibitors are undergoing clinical testing in humans as
chemotherapeutics [76]. Recently, these compounds have also been tested in diabetic animals and
these studies have proven the benefit of HSPC blockade in diabetic complications.
3.3.1. Diabetic Nephropathy
In the normal kidney, HSPC is highly expressed in the outer medulla where it interacts with the steroid
hormone receptor. Within the glomeruli HSPC is present predominantly in mesangial cells and podocytes.
We did not observe any change in HSPC expression in either the kidney of DM1 animals or glomerular
cells exposed in vitro to high glucose and mechanical stretch [27] and another group has even reported a
HSPC downregulation in the renal cortex of DM2 mice [77]. Despite the lack of HSPC overexpression,
intervention studies have shown that HSPC inhibition is beneficial in DN. In db/db mice fed with a
HFD, the HSPC inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG)
preserved kidney function, ameliorated both glomerular and tubular damage, and improved
survival [78]. Because HSPC also modulate lipid homeostasis [79], amelioration of lipid profile
may partially explain the renal benefit in this model of combined hyperglycemia and dyslipidemia.
However, a more recent study in STZ-induced diabetic ApoE−/− mice has shown that 17-DMAG can
reduce albuminuria, mesangial expansion, and inflammation independently of both hyperglycemia
and dyslipidemia [80]. This benefit may be due to reduced inflammation as HSPC inhibition
diminished both NF-κB and the activation of signal transducer and activator of transcription (STAT),
and HSPC is known to stabilise two kinases (IKK and JAK2) that activate the NF-κB and STAT
pathways. Alternatively, the renal protective effect may be secondary to HSF-1-mediated HSPA/HSP70
induction [80]. Furthermore, an inhibitory effect on the TGF-β1 pathway cannot be excluded based on
recent studies showing an anti-fibrotic effect of HSPC blockade [81–83].
3.3.2. Diabetic Retinopathy
HSPC is highly expressed in the rat retina [84] and undergoes downregulation in OLETF rats,
a model of DM2 [85]. This downregulation is believed to contribute to RGC apoptosis, as HSPC is
important in stabilising the phosphorylated form of the signalling molecule Akt that plays a key role
in RGC survival. On the other hand, HSPC may also be deleterious in DR because HSPC stabilises the
transcription factor hypoxia-inducible factor (HIF)-1 that induces the expression of pro-angiogenic
factors involved in the development of proliferative DR. Consistent with this, the HSPC inhibitor
geldanamycin and its derivative 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) abolished the
release of the angiogenic factors VEGF, integrin-linked kinase (ILK), and stromal cell-derived factor (SDF)-1
in cultured retinal pigment epithelial cells [86,87]. In addition, two novel HSPC blockers, the deguelin
analogues SH-1242 and SH-1280, reduced both HIF-1 half-life and VEGF upregulation in vivo and
suppressed hypoxia-mediated retinal neovascularization [88]. These compounds also inhibited
vascular leakage in a model of STZ-induced DM, suggesting a potential benefit in DM-induced
macular oedema [88]. Therefore, potential therapeutic strategies targeting HSPC in DR should be
fine-tuned in order to antagonize hypoxia-induced angiogenesis without enhancing apoptosis.
3.3.3. Diabetic Neuropathy
HSPC inhibition has been used as a strategy to increase the expression of neuroprotective
HSPA/HSP70 [89]. In STZ-induced diabetic mice, treatment with the HSPC inhibitor KU-32 reversed
both sensory hypoalgesia and altered nerve conduction velocity (NCV). This occurred through
induction of HSPA/HSP70 as no benefit was observed in HSPA/HSP70 knockout animals [90]. In most
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diabetic animals, reversal of these functional deficits was associated with an increased density of
intra-epidermal nerve fibre bundles [91], indicating that the clinical benefit of HSPC inhibition was
mainly due to fibre regeneration. In addition, in vitro KU-32 prevented high glucose-induced death of
DRG neurons and decreased neuregulin-1 (NRG-1)-induced demyelination [90]. A recent study has
clarified the underlying mechanism by showing that KU-32-induced HSPA/HSP70 upregulation causes
proteosomal degradation of c-Jun, a downstream signalling molecule of NRG-1 [92]. Improvement
of mitochondrial bioenergetics has recently emerged as another mechanism of the neuroprotective
effects of KU-32. In vitro, KU-32 decreased hyperglycemia-induced oxidative stress and improved
mitochondrial bioenergetics in sensory neurons [93]. Moreover, ex vivo maximal respiratory capacity
was reduced in sensory neurons isolated from STZ-induced diabetic animals and HSPC inhibition
ameliorated this abnormality in vivo [91] in an HSPA/HSP70-dependent manner [94].
3.3.4. Diabetes Macrovascular Complications
A decline in vascular bioavailability of nitric oxide (NO) is a key determinant of endothelial
dysfunction in DM [95]. The formation of a complex between HSPC and endothelial NO synthase
(eNOS) is a prerequisite for subsequent Akt-mediated eNOS activation resulting in NO generation.
Therefore, several studies explored whether formation of HSPC-eNOS complexes is altered in DM.
HSPC-eNOS complexes were reduced in the aortic endothelium of diabetic rats [96]. Moreover,
in vitro exposure of endothelial cells to high glucose reduced formation of HSPC-eNOS complexes
because high glucose decreased HSPC expression, promoted HSPC translocation to the cell surface,
and enhanced HSPC interaction with alternative clients as IKKβ [96–98]. In contrast, metformin
enhanced HSPC-eNOS interaction by inducing eNOS phosphorylation [99]. Therefore, DM can impair
NO formation at least in part by reducing the stabilising effect of HSPC on eNOS.
However, studies in both human and experimental atherosclerosis suggest that HSPC may be
deleterious and that HSPC inhibition may represent a potential therapeutic strategy in macrovascular
diseases. In human atherosclerotic lesions, there was a HSPC upregulation [100], particularly in the
unstable shoulder region of the plaque, while stable plaques were enriched in HSPA/HSP70 [101].
In addition, serum HSPC levels were higher in patients with atherosclerosis and antibodies against
HSPC were detected exclusively in atherosclerotic patients and not in healthy controls [100].
Treatment of STZ-induced diabetic ApoE−/− mice with the HSPC inhibitor 17-DMAG significantly
reduced atherosclerotic lesions and induced a more stable plaque phenotype [80]. Similarly, HSPC
inhibition diminished both lesion size and inflammation in STZ-induced diabetic animals [102].
These atheroprotective effects of HSPC inhibition were likely due to HSPA/HSP70 induction and/or
inhibition of transcription factors affecting both inflammation and oxidative stress (nuclear factor
erythroid-derived like 2 or Nrf2, NF-κB, STAT) [80,102].
On the other hand, HSPC and in particular HSP90α can be beneficial in wound healing. Topical
application of a fragment of secreted HSP90α (F-5) accelerated diabetic wound healing in mice and showed
greater efficacy compared to other growth factors because it enhanced both epidermal and dermal cell
recruitment overriding the inhibitory effects of hyperglycemia and TGF-β1 on cell migration [103].
In conclusion, HSPC has both beneficial and deleterious effects in the context of DM macrovascular
diseases. Despite the availability of specific HSPC inhibitors, it is thus difficult to pharmacologically
reduce HSPC activity without causing relevant unwanted side effects.
In summary, levels of HSPC are either unchanged or downregulated in microvascular
complications, while an HSPC overexpression is observed in stable regions of atherosclerotic plaques.
HSPC inhibition was shown to be beneficial in all micro and macrovascular diabetes complications
with the exception of diabetic wounds where a benefit of treatment with HSP90α was proven.
3.4. Heat Shock Protein A—HSP70
In humans, constitutive HSC70/HSP73 and inducible HSP72/iHSP70 are the major members
of the HSPA/HSP70 family. HSPA/HSP70 favours protein (re)-folding, transports proteins through
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membranes to enable their delivery to organelles, it recruits proteins to the proteasome for turnover,
and brings proteins to the endosome/lysosome compartment for autophagy. These diverse functions
are accomplished by interactions with a variety of partners, including HSPC/HSP90, J proteins,
negative regulatory factors (NEFs), lysosome-associated membrane protein 2A (LAMP-2A), and even
lipids. In addition, HSPA/HSP70 blocks multiple apoptotic pathways and inhibits inflammation
by sequestering NF-κB. Moreover, HSPA/HSP70 is induced by oxidative stress and prevents
NF-κB-induced iNOS expression thereby limiting generation of both reactive oxygen species (ROS)
and peroxynitrite. More recently, accumulating evidence indicates a role of extracellular HSPA/HSP70
as a modulator of inflammatory and immune processes [104].
3.4.1. Diabetic Nephropathy
In the normal kidney, HSPA/HSP70 expression increases progressively along the cortico-papillary
axis in parallel with the osmotic gradient [105]. In STZ-induced diabetic rats, HSPA/HSP70
was upregulated in the outer medulla, while glomerular expression was only modesty increased
and exclusively in early DN [27]. Data on HSPA/HSP70 expression in cortical tubules are
conflicting [27,77,106–110]; however, a recent study on kidney biopsies from patients with DN has
shown an upregulation of HSPA/HSP70 in the cortical tubules [111]. Moreover, in vitro HSPA/HSP70
was overexpressed in both tubular cells exposed to high glucose and renal interstitial fibroblasts
exposed to AGEs [107,108,110].
As described above, HSPA/HSP70 induction using HSPC inhibitors was beneficial in experimental
models of early DN; however, recent evidence suggests that extracellular HSPA/HSP70 may favour
DN progression by promoting tubule-interstitial inflammation. In vitro in proximal tubule cells,
albumin strongly induced the release of eHSPA/eHSP70 that, in turn, triggered the overexpression of
the inflammatory cytokines monocyte chemoattractant proteins 1 (MCP-1), tumor necrosis factor alpha
(TNF-α), and macrophage inflammatory protein 2 (MIP2) via a TLR4-NF-κB pathway [111]. Likewise,
in vivo in STZ-induced diabetic animals both TLR4 and HSPA/HSP70 were overexpressed in the
tubules and either TLR4 deletion or treatment with a variety of HSPA/HSP70 inhibitors, acting on
either intra or extracellular HSPA/HSP70, reduced albuminuria and markers of both inflammation and
tubular injury [111]. Therefore, HSPA/HSP70 may be beneficial in early DN because of its intracellular
cytoprotective activity, but when albuminuria develops extracellular HSPA/HSP70 may contribute to
the tubular-interstitial damage that is a key driver of DN progression. Consistent with this, a small
study performed in patients with DM2 showed an association between urinary HSPA/HSP70 levels
and albuminuria [112]. Moreover, serum HSPA/HSP70 levels were higher in DM2 patients with
albuminuria [113] and polymorphisms of the HSPA/HSP70 gene were associated with DN in DM2
patients [114].
3.4.2. Diabetic Retinopathy
Expression of HSPA/HSP70 is globally enhanced in both diabetic retinas and retinal endothelial
cells exposed to high glucose. There are also changes in HSPA/HSP70 distribution as HSPA/HSP70
was increased in the cytosol and reduced in the mitochondria [115]. Formation of complexes
between HSPA/HSP70 and the matrix metallopeptidase 9 (MMP-9) was enhanced in murine diabetic
retinas and this is of relevance because oxidative stress-induced MMP-9 activation plays a key role
in DM-induced mitochondrial abnormalities leading to retinal endothelial cell apoptosis. Indeed,
knocking-down MMP-9 in either diabetic animals or retinal endothelial cells exposed to high glucose
reversed apoptosis, mitochondrial alterations, and abnormalities in HSPA/HSP70 both expression
and distribution. The specific role of HSPA/HSP70 in this process has been only partially clarified;
however, HSPA/HSP70 may be important in chaperoning MMP-9 to the mitochondria and thus in
enhancing MMP-9-induced mitochondrial damage [115].
Data on the circulating levels of both HSPA/HSP70 and anti-HSPA/HSP70 antibodies in DR
are scarce. However, a study in patients with DM2 reported a rise in serum HSPA/HSP70 levels in
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patients with DR (n = 50) compared with subjects without DR (n = 50) [116], while anti-HSPA/HSP70
levels were negatively and independently associated with DR in the large cohort of patients with DM1
in the EURODIAB PCS [117].
3.4.3. Diabetic Neuropathy
HSPA/HSP70 has neuroprotective effects in a variety of neurological conditions. In the context of
DM, several studies have shown that HSPA/HSP70 increases the ability of both neurons and Schwann
cells to tolerate on-going diabetic insults by improving oxidative stress, mitochondrial function,
and possibly inflammation, as recently reviewed [118]. In cultured sensory neurons, induction of
HSPA/HSP70 increased the expression of the anti-oxidant enzyme superoxide dismutase 2 (SOD2).
In diabetic animals, HSPA/HSP70 induction ameliorated DSP and abolished DRG overexpression
of two pro-oxidant proteins: the enzyme NADPH oxidase 2 (NOX2) and thioredoxin interacting
protein [93,94] that enhances oxidative stress by inhibiting anti-oxidant thioredoxin. HSPA/HSP70
is also believed to improve mitochondrial bioenergetics. Although pharmacological induction of
HSPA/HSP70 does not modify mitochondrial protein expression, most mitochondrial proteins are
imported to the mitochondria after transcription and the key role of HSPA/HSP70 in this transfer may
explain its beneficial effect [94]. Finally, HSPA/HSP70 has an anti-inflammatory activity in neurons,
predominantly due to a reduction in NF-κB activity. Intervention studies proving the relevance of
HSPA/HSP70 in DSP have been performed using HSPC inhibitors to induce HSPA/HSP70 expression
and they have been reported above.
3.4.4. Diabetic Macrovascular Diseases
HSPA/HSP70 expression is enhanced in human atherosclerotic lesions. Moreover, in vitro studies
have shown that oxidized LDLs can induce HSPA/HSP70 expression in activated macrophages,
endothelial cells, and vascular smooth muscle cells. As HSPA/HSP70 is cytoprotective, this
overexpression may be a reactive response aimed to limit atherogenic stressors-induced damage [119].
There is relatively little information on HSPA/HSP70 in diabetic macrovascular diseases; however,
a recent study has shown that HSPA/HSP70 induction can ameliorate vascular dysfunction secondary
to insulin-resistance [120]. Moreover, a HSPA/HSP70 polymorphism was associated in patients with
DM2 with both cerebral ischemic events and the presence of unstable plaques [121].
HSPA/HSP70 can also be exposed on the plasma membrane in stressed cells and/or released
into the extracellular space and subsequently into the bloodstream either through passive secretion
or as a result of necrotic cell death [119,122]. The observation that serum HSPA/HSP70 levels
are enhanced in patients with DM and correlate with C reactive protein (CRP) levels suggests
that diabetes-related insults can enhance exposure/release of HSPA/HSP70 [123]. Extracellular
HSPA/HSP70 has important modulatory effects on both innate and adaptive immunity, as recently
reviewed [104], acting either as a cross-presenter of immunogenic peptides via major histocompatibility
complex (MHC) antigens or as a chaperokine. Although eHSPA/eHSP70 appears to enhance both
inflammatory and immune responses, recent studies suggest that eHSPA/eHSP70 can also have
important anti-inflammatory effects, as recently reviewed [124] by activating both immunosuppressive
regulatory T cells (Treg) and sialic acid-binding immunoglobulin superfamily lectin (SIGLEC) receptors
that block inflammatory processes through direct interaction with the TLRs [125]. Clinical studies
in the general population have reported an inverse association between levels of HSPA/HSP70 and
anti-HSPA/HSP70 and both the presence and the severity of cardiovascular diseases (CVD) [126–129].
Furthermore, lower HSPA/HSP70 levels were a predictor of future development of atherosclerosis
in subjects with established hypertension [130]. Similarly, our study on patients with DM1 from
the EURODIAB PCS showed that serum anti-HSP70 antibody levels in the upper quartiles were
associated with an almost 50% lower likelihood of micro- and macrovascular complications with
respect to lower values, independently of conventional risk factors and markers of both inflammation
and endothelial dysfunction. Subgroup analysis revealed a significant association with both DR and
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CVD [117]. Therefore, clinical data in subjects with and without DM suggest that HSPA/HSP70 and
anti- HSPA/HSP70 are protective markers in CVD.
In summary, HSPA/HSP70 expression is either unchanged or more often increased in diabetic
complications, including macrovascular diseases. HSPA induction using a HSPC inhibitor has
beneficial effects in both diabetic nephropathy and neuropathy. However, eHSPA/eHSP70 can
promote DN progression by enhancing tubule-interstitium inflammation. Circulating levels of
anti-HSPA/HSP70 are a protective marker in CVD.
3.5. Heat Shock Protein D1—HSP60
HSPD1/HSP60 is a type I chaperonin and together with its co-chaperone HSPE1/HSP10 forms a
chaperone system specific of the mitochondria. HSPD1/HSP60 has a central hydrophobic cavity that
provides an isolated environment for both de novo protein folding and matrix protein refolding, and its
chaperone activity is ATP-dependent. HSPD1/HSP60 is essential for the maintenance of mitochondrial
both activity and biogenesis and undergoes upregulation in response to mitochondrial impairment,
being thus considered a marker of mitochondrial stress [131]. Under stress conditions, HSPD1/HSP60
is also found in the cytosol, on the cell surface acting as a signal molecule for the immune system,
and in the extracellular space where it can regulate both inflammatory and immune processes.
3.5.1. Microvascular Complications
In the normal kidney, HSPD1/HSP60 content is greater in renal cortex and outer medulla with
a distribution that mirrors the abundance of mitochondria [105]. Renal HSPD1/HSP60 expression
was increased in STZ-induced diabetic rats, particularly in the outer medulla, whereas no changes
were found in both the glomeruli and glomerular cells exposed to high glucose [27]. At variance with
these results, a proteomic analysis performed on renal tissue from STZ-induced diabetic rats reported
a marked HSPD1/HSP60 downregulation [132], though renal distribution was not described. Recently,
a global network investigation of previous proteomic analyses in DN has identified HSPD1/HSP60 as
a central node in protein-to-protein interaction. Functional validation performed by studying tubular
cells exposed in vitro to high glucose has shown that HSPD1/HSP60 silencing can modestly diminish
high glucose-induced cell dysfunction [133].
Few studies assessed HSPD1/HSP60 in other microvascular complications. In the diabetic retina,
HSPD1/HSP60 expression was globally enhanced, but reduced in the mitochondria, suggesting
DM-induced mitochondrial stress. Moreover, in retinal endothelial cells, increased mitochondrial
MMP-2 activity was shown to alter mitochondrial integrity by modulating both HSPD1/HSP60 and
connexin-43 and allowing cytochrome c to leak out with activation of the apoptotic machinery [134].
Finally, HSPD1/HSP60 was overexpressed in the cell bodies of CA1 and CA3 hippocampal
neurons of STZ-induced diabetic rats together with enhanced hippocampal levels of manganese
superoxide dismutase enzyme (MnSOD) [135], suggesting that oxidative stress may induce a
compensatory HSPD1/HSP60 overexpression in the CNS.
3.5.2. Macrovascular Complications
In both humans and murine models of atherosclerosis, there is evidence of HSPD1/HSP60
overexpression in atherosclerotic lesions [136–138], peaking in early and decreasing in advanced
lesions [136].
Moreover, exposure of endothelial cells to various stresses, including DM-associated stresses,
induced HSPD1/HSP60 both expression on the cell surface and extracellular release, as recently
reviewed [138]. Extracellular HSPD1/HSP60 can have direct auto/paracrine pro-inflammatory effects.
For instance, exposure of VSMCs to platelet-derived growth factor BB (PDGF-BB) enhanced the release of
HSPD1/HSP60 that, in turn, induced VSMCs migration via a TLR4-ERK-dependent mechanism [139].
Furthermore, HSPD1/HSP60 exposure/release can also elicit an immune/autoimmune reaction.
All subjects acquire adaptive immunity against bacterial HSP60/65 by infection and, because there
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is a high degree of homology between mammalian and bacterial HSPD1/HSP60, this can trigger
an immune cross-reaction against human HSPD1/HSP60. Furthermore, chemically altered human
HSPD1/HSP60, derived from either damaged or necrotic cells, can also induce an autoimmune reaction
against human HSPD1/HSP60 [138,140]. Studies performed in animal models of atherosclerosis suggest
that this immune/autoimmune reaction can contribute to atherogenesis. T-cell clones recognizing
HSPD1/HSP60 were found in atherosclerotic plaques and immunization with HSP60/65 increased
atherosclerosis in animals [141–143]. Moreover, in healthy subjects the prevalence of early atherosclerotic
lesions was associated with anti-HSPD1/HSP60 reactivity of peripheral T cells [144,145], and both
cross-sectional and prospective studies showed a direct association between anti-HSP60/65 levels and
CVD [138,146–148]. Moreover, HSPD1/HSP60 autoantibodies, isolated from patients with CVD, could
promote atherosclerosis in ApoE−/− mice. Of interest, this effect was prevented by mice pre-immunization
with the F(ab)2 segments of the human-derived HSPD1/HSP60 antibody [149], raising the possibility that
tolerizing vaccines may represent a therapeutic strategy in atherosclerosis [150].
By comparison there is relatively little information on HSPD1/HSP60 in patients with DM and
CVD. However, a cross-sectional study performed on 855 patients with DM2 showed that the percentage
of subjects with detectable circulating levels of HSPD1/HSP60 was greater in patients with CVD as
compared to subjects without CVD and an history of myocardial infarction was associated with higher
levels of HSPD1/HSP60 [151]. Another study reported that patients with both DM2 and peripheral
vascular disease had anti-HSP60/65 levels comparable to healthy controls [152]. Similarly, we did not
observe any change in circulating anti-HSPD1/HSP60 levels in DM1 patients with and without CVD [117].
In summary, HSPD1/HSP60 is globally enhanced in diabetic complications, though a
reduction of mitochondrial HSPD1/HSP60 has been reported in diabetic retinopathy, suggesting
mitochondrial stress resulting in translocation of HSPD1/HSP60 from the mitochondria to the cell
membrane/extracellular space where HSPD1/HSP60 can elicit an immune/autoimmune reaction
contributing to cell damage.
4. Summary of Evidence
Given their key role in cytoprotection, HSPs can theoretically counteract the deleterious effects
of diabetes in target cells of diabetes chronic complications (Figure 3). Overall data reported above
show that expression of HSPs is modulated in diabetic complications with preliminary proof of
functional relevance; however, the strength of evidence varies by complication. In the diabetic kidney,
there was HSP47 upregulation likely involved in renal fibrosis, but expression of cytoprotective
HSP27, HSPC/HSP90, HSPA/HSP70, and HSPD1/HSP60 was unchanged in the renal cortex of
animals with type 1 diabetes and both HSPC/HSP90 and HSPD1/HSP60 were even downregulated
in other models of diabetes. This indicates an overall insufficiency of the compensatory HSP
response to diabetes-induced stresses within the kidney. Consistent with this notion, enhanced
HSP transcription by inhibiting HSPC/HSP90 was beneficial. In addition, phosphorylated HSPB1 and
eHSPA/eHSP70 were enhanced in podocytes and tubular cells, respectively, and both these changes
are potentially deleterious as phosphorylated HSPB1 may favour proteinuria and eHSPA/eHSP70
promotes tubule-interstitial inflammation. Therefore, in the kidney the HSP machinery fails to confer
protection and some changes may even be detrimental. Similarly, in the retina, diabetes does not
evoke the expected HSP response as total HSPB1 was unchanged, HSPD1/HSP60 was reduced in the
mitochondria, HSPC/HSP90 was downregulated and only HSPA/HSP70 underwent upregulation.
However, there are no intervention studies proving functional relevance with the exception of a protective
effect of HSPA/HSP90 inhibition through downregulation of angiogenic factors involved in PDR.
More convincing evidence for a functional role of HSP is available in DSP. Although HSP
expression measurement only showed an upregulation of HSPB1 and HSPD1/HSP60, intervention
studies proved amelioration of DSP in experimental animals either overexpressing HSPB1 or treated with
HSPC/HSP90 to induce HSPA/HSP70. Therefore, boosting the HSP response results in neuroprotection,
strongly suggesting that HSP expression in the diabetic neurons is inadequate to counteract cellular stresses.
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Figure 3. Cytoprotective Effects of HSPs in Diabetes. HSP90 binds to the transcription factor
HSF1 and keeps it in an inactive state. If HSP90 is required elsewhere, free HSF1 moves to
the nuclei and induces HSP transcription. HSP90 facilitates the maturation of several proteins,
known as HSP90 “clients”. HSPB1/HSP27 forms high molecular weight multimers that stabilize
the cytoskeleton, but the phosphorylat d form loses its ctin-capping activity. HSP60 is located
in the mitochondria a d HSP70 shuttle cytosolic protein to the mit cho dria. Diabe e causes cell
damage by inducing oxi ative stress, inflammation, protein damage, cyt skeleton remodeling, and
apoptosis (red squares). Diabetes-induced misfolded proteins either are rescue by HSPs or undergo
proteasome degradation. Besides favoring protein refolding, HSPB1/HSP27 prevents apoptosis
and reduces oxidative stress (red T symbols) by increasing both glutathione (GSH) levels and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) activity. HSP70 inhibits apoptosis and reduces
NF-κB-dependent inflammation (red T symbols) with consequent reduction of oxidative stress.
At variance with microvascular complic ti s, most HSP (HSPC/HSP90, HSPA/HSP70,
HSPD1/HSP60) were upregulated in macrovascular disease with the exception of both intra and
extracellular HSPB1 that underwent downregulation. However, data were predominantly obtained in
non-diabetic atherosclerotic mice and it would be important to obtain data in diabetic animals to clarify
if diabetes itself is responsible of the failure to induce a normal stress response. However, both HSPB1
overexpression and HSPC/HSP90 inhibition ameliorated the phenotype of the atherosclerotic plaques
in diabetic animals, confirming the presence of a relative deficiency in HSPs in CVD. Data on diabetic
wounds are scarce; howev r, av ilable result ind cate that insufficient HSP47 may interfere with
wound repair, while HSP90-α accelerates healing.
5. Limits of Current Research and Future Perspective
Research on HSPs in the field of diabetic complications has important limitations. Changes
in HSP expression in target organs of DM complications are difficult to interpret as a rise in HSP
expression may suggest a direct involvement of HSPs in the pathogenic process, a compensatory
cytoprotective response or even both in different stages of the disease. For instance, HSPB1 expression
was found enhanced in diabetic DRG and this may suggest either a compensatory rise to protect
neurons or a mechanism of diabetes-induced neuron injury. Intervention studies have clarified that
HSPB1 is protective, but its induction is insufficient, as greater HSPB1 levels are required to confer
neuroprotection. Moreover, intra and extracellular HSPs often have opposing effects and studies
assessing HSP protein expression cannot discriminate between the two, making difficult to draw any
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conclusion. For example, intracellular HSPA/HSP70 has cytoprotective effects that are important in
defending renal cells exposed to a diabetic milieu, while eHSPA/eHSP70 causes tubule-interstitial
damage. These opposing effects of intra/extracellular HSPs may also provide a possible explanation for
the highly conflicting results on expression of HSPs in diabetic complications. Therefore, intervention
studies targeting specifically either intra or extracellular HSPs are required to gain a deeper insight on
the functional role of HSP in DM complications.
HSPs can also be released outside cells in extracellular vesicles (EVs) that are an important new
mechanism of cell-to-cell communication. EVs are enriched in HSPA/HSP70, though other HSPs,
including HSPB1 and HSPC/HSP90, have also been found. Delivery of HSPs via EVs is very effective
as HSPs are present in high concentrations in EVs and they can synergize with other factors enclosed
within EVs [153]. For instance, activation of macrophages by HSPA/HSP70 carried by EVs was more
than 250-fold higher than the same concentration of the HSP70 in solution [154]. The role of HSPs
carried by EVs has been explored mainly in cancer and immunology. However, there is preliminary
evidence of relevance in diabetes and associated complications. For example, HSP20 has been recently
shown to improve diabetic cardiomyopathy by increasing the release of EVs enriched in HSP20 and
other cardioprotective factors [155]. Moreover, fibrocytes-derived exosomes, enriched in HSP90α,
accelerated wound closure in diabetic mice in vivo [156]. This is emerging area of research that is
expected to grow exponentially in the near future.
It is increasing recognised that HSPs act in a network; therefore, abnormalities of clusters of
HSPs are of great relevance. Consistent with this view, repression of ATP-dependent and induction of
ATP-independent HSPs has been recently demonstrated in both aging and neurodegenerative diseases [157].
This aspect requires consideration in future research in the diabetes field as it would be important to move
from detection of abnormalities in the expression of individual HSPs to the identification of clusters of
changes in the chaperome that are of functional relevance and may contribute to insufficient proteostasis.
There is great interest on the potential use of HSPs as therapeutic targets. Because DM causes
accumulation of damaged proteins, oxidative stress, altered mitochondrial bioenergetics, and apoptosis,
boosting the HSP cytoprotective machinery appears an ideal strategy to prevent and/or reduce the
progression of DM complications and available data in experimental animals support this hypothesis.
Moreover, the recent development in cancer research of compounds that can rise/lower HSP levels
in a specific and safe manner has open the way to pharmacological intervention studies targeting
HSPs also in others pathological conditions, including DM-related complications (Table 2). In this
respect, newly developed HSPC/HSP90 inhibitors appear very promising. Moreover, Fv-HSP70,
a fusion molecule of HSPA/HSP70 to the single-chain Fv fragment of a cell-penetrating antibody,
can be used for the intracellular delivery of HSPA/HSP70 and has been recently proven safe in
humans [158]. However, given the multitude of HSP functions, their pharmacological modulation
may cause undesired effects; therefore, development of compounds targeting specific HSP-client
interactions and/or HSP functions would be crucial in pathological conditions requiring long-term
therapy as DM complications. Tissue-targeting strategies may also be valuable as pharmacological
modulation of HSPs can have opposing effects in different vascular beds of DM complications.
There is an increasing need to identify novel biomarkers of DM complications particularly in
view of potential applications in precision medicine. Available data suggest that circulating both HSP
and anti-HSP levels may be exploited as biomarkers of diabetic vascular diseases (Table 3); however,
studies performed in this area have important limits. They are often conducted on small groups of
patients and without adjustment for conventional risk factors and confounders. Sometimes patients
with diabetic complications are compared with healthy subjects, not taking into account that DM
itself can affect HSP circulating levels. Finally, there are insufficient prospective studies assessing the
importance of HSPs/anti-HSPs in predicting outcomes and guiding intervention. Therefore, it would
important in the future not only to identify independent associations between HSPs/anti-HSPs and
DM complications in large cohorts of well-characterised patients with DM, but also to prospectively
validate promising biomarkers for future applications in clinical practise.
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Table 2. Summary of Intervention Studies Targeting HSPs in Animal Models of Diabetic Complications.
HSP Action Strategy Specificity Complication Animal Model Effects Reference
HSP27
Inhibition of
phosphorylation Genetic deletion of MK-2 +/− Diabetic nephropathy
STZ-induced diabetic
MK-2−/− mice None [29]
Inhibition of
phosphorylation PHA666859 (p38 inhibitor) - Diabetic retinopathy STZ-induced diabetic rats
Amelioration of retinal
vascular injury [38]
Induction Genetic overexpression + Diabetic neuropathy STZ-induced diabetic hHSP27transgenic mice Amelioration of DSP [52]
HSP90
Inhibition 17-DMAG(HSP90 inhibitor) + Diabetic nephropathy db/db mice HFD
Reduced kidney
damage [78]







Inhibition SH-1242/SH-1280(HSP90 inhibitors) + Diabetic retinopathy STZ-induced diabetic mice
Reduced retinal
vascular leakage [88]
Inhibition KU-32 (C-terminalHSP90 inhibitor) + Diabetic neuropathy STZ-induced diabetic mice Amelioration of DSP [90]







and more stable plaques
[80]
Inhibition 17-DMAG(HSP90 inhibitor) +
Diabetic
macrovascular disease STZ-induced diabetic mice
Reduced lesion size and
inflammation [102]
HSP70
Inhibition PFTµ/ VER (intracellularHSP70 inhibitors) + Diabetic nephropathy STZ-induced diabetic mice
Reduced albuminuria,
tubular injury [111]
Inhibition KNK437 (HSF-1 inhibitor) +/− Diabetic nephropathy STZ-induced diabetic mice Reduced albuminuriatubular injury [111]
Inhibition HSP70 neutralizing Ab(blockade of eHSP70) + Diabetic nephropathy STZ-induced diabetic mice Reduce albuminuria [111]
MK-2: MAP kinase-activated protein kinase 2; STZ: streptozotocin; DSP: distal symmetric polyneuropathy; 17-DMAG: 17-dimethylaminoethylamino-17-demethoxygeldanamycin;
eHSP70: extracellular HSP70. HSP27 = HSPB1; HSP90 = HSPC; HSP70 = HSPA.
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Table 3. Summary of Clinical Studies on Circulating HSP and anti-HSP Levels in Patients with Diabetic Complications.







DM2 = 195 (DR = 123,
DN = 80, DNu = 109)
HSP27 higher in DM2-DN vs.
other groups Gender, age, BMI [33]
Nested case-control study
EURODIAB PCS














Inverse association with nerve
function OR 2.51 (1.25, 5.05)
Age, sex, statin,
HbA1c [56]
Anti-HSP27 Nested case-control studyEURODIAB PCS










Urinary HSP70 Case-control study DM2 (Normo, MicroMacro) vs. C
C = 15
DM2 = 45 (Normo = 15
Micro = 15, Macro = 15)
Urinary HSP70 higher in
Micro/Macro than in Normo DM2 None [112]
HSP70
Case-control study DM2 with and withoutalbuminuria
DM2-Normo = 40
DM2-Alb = 40
HSP70 higher in Alb than in
Normo DM2 None [113]
Case-control study DM2 with and withoutDR vs. C
C = 70
DM2 without DR = 50
DM2 with DR = 50
HSP70 higher in DM2 with DR None [116]






with DR [OR 0.35 (0.15–0.80)] and











DM without CVD = 607
DM with CVD = 241
HSP60 detectable more frequently
in subjects with CVD and MI
Age, sex, ethnic
group, smoking [151]
Anti-HSP60 Nested case-control studyEURODIAB PCS
DM1 with and without
complications
Controls = 168
Cases = 363 No associations - [117]
C: healthy controls, DM1: type 1 diabetes, DM2: type 2 diabetes, NGT: normal glucose tolerance, IGT: impaired glucose tolerance, Normo: normoalbuminuria, Micro: microalbuminuria;
Macro: macroalbuminuria; Alb: albuminuria; DR: diabetic retinopathy; DN: diabetic nephropathy; DNu: diabetic neuropathy; CVD: cardiovascular diseases; DSP: distal symmetric
polyneuropathy; MI: myocardial infarction; AER: albumin excretion rate, TNF-α: tumor necrosis factor. N: number.
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